These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 20183930)

  • 1. Off-label use of bevacizumab: advanced adenocarcinoma of the pancreas.
    Technol Eval Cent Assess Program Exec Summ; 2009 Oct; 24(4):1-3. PubMed ID: 20183930
    [No Abstract]   [Full Text] [Related]  

  • 2. Off-label uses of bevacizumab: renal cell carcinoma and other miscellaneous non-colorectal cancer indications.
    Technol Eval Cent Assess Program Exec Summ; 2006 Oct; 21(9):1-4. PubMed ID: 17061399
    [No Abstract]   [Full Text] [Related]  

  • 3. 10 Questions about the use of bevacizumab in the management of recurrent malignant gliomas.
    Chamberlain MC
    Neurologist; 2010 Jan; 16(1):56-60. PubMed ID: 20065801
    [No Abstract]   [Full Text] [Related]  

  • 4. Reputation and precedent in the bevacizumab decision.
    Carpenter D; Kesselheim AS; Joffe S
    N Engl J Med; 2011 Jul; 365(2):e3. PubMed ID: 21707383
    [No Abstract]   [Full Text] [Related]  

  • 5. Position paper: the need for head-to-head studies comparing Avastin versus Lucentis.
    Schmucker C; Antes G; Lelgemann M
    Surv Ophthalmol; 2009; 54(6):705-7. PubMed ID: 19818262
    [No Abstract]   [Full Text] [Related]  

  • 6. FDA drug approval summary: bevacizumab (Avastin) plus Carboplatin and Paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer.
    Cohen MH; Gootenberg J; Keegan P; Pazdur R
    Oncologist; 2007 Jun; 12(6):713-8. PubMed ID: 17602060
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Off-label uses of bevacizumab: breast and lung cancer indications.
    Technol Eval Cent Assess Program Exec Summ; 2006 Oct; 21(8):1-4. PubMed ID: 17061398
    [No Abstract]   [Full Text] [Related]  

  • 8. Off-label uses of sorafenib and sunitinib.
    Technol Eval Cent Assess Program Exec Summ; 2008 Feb; 22(11):1-4. PubMed ID: 18411502
    [No Abstract]   [Full Text] [Related]  

  • 9. Phase III multicenter randomized clinical trial to evaluate the safety and efficacy of CoFactor/5-fluorouracil/bevacizumab versus leucovorin/5-fluorouracil/bevacizumab as initial treatment for metastatic colorectal carcinoma.
    Saif MW; Merritt J; Robbins J; Stewart J; Schupp J
    Clin Colorectal Cancer; 2006 Sep; 6(3):229-34. PubMed ID: 17026795
    [No Abstract]   [Full Text] [Related]  

  • 10. Clinical use of anti-vascular endothelial growth factor monoclonal antibodies in metastatic colorectal cancer.
    Chase JL
    Pharmacotherapy; 2008 Nov; 28(11 Pt 2):23S-30S. PubMed ID: 18980549
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Target practice: lessons from phase III trials with bevacizumab and vatalanib in the treatment of advanced colorectal cancer.
    Los M; Roodhart JM; Voest EE
    Oncologist; 2007 Apr; 12(4):443-50. PubMed ID: 17470687
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Avastin saga reveals debate over clinical trial endpoints.
    Sharma SP
    J Natl Cancer Inst; 2012 Jun; 104(11):800-1. PubMed ID: 22673590
    [No Abstract]   [Full Text] [Related]  

  • 13. Avastin hearing leads to more uncertainty over drug's future.
    Goozner M
    J Natl Cancer Inst; 2011 Aug; 103(15):1148-50. PubMed ID: 21768534
    [No Abstract]   [Full Text] [Related]  

  • 14. Bevacizumab: improved survival at what cost?
    Kolesar JM
    Am J Health Syst Pharm; 2005 May; 62(10):1017. PubMed ID: 15901584
    [No Abstract]   [Full Text] [Related]  

  • 15. Avastin's uncertain future in breast cancer treatment.
    Twombly R
    J Natl Cancer Inst; 2011 Mar; 103(6):458-60. PubMed ID: 21393607
    [No Abstract]   [Full Text] [Related]  

  • 16. The effects of bevacizumab on postoperative complications in patients undergoing colorectal and pancreatic cancer resection.
    Cheon EC; Small W; Strouch MJ; Krantz SB; Rademaker A; Mulcahy MF; Benson AB; Bentrem DJ; Talamonti MS
    J Surg Oncol; 2010 Oct; 102(5):539-42. PubMed ID: 20812264
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FDA cancels approval for bevacizumab in advanced breast cancer.
    Tanne JH
    BMJ; 2011 Nov; 343():d7684. PubMed ID: 22121166
    [No Abstract]   [Full Text] [Related]  

  • 18. Bevacizumab for advanced colorectal cancer.
    Hadj Tahar A
    Issues Emerg Health Technol; 2004 Dec; (63):1-4. PubMed ID: 15612152
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pushing the envelope.
    Nat Biotechnol; 2011 Aug; 29(8):669. PubMed ID: 21822220
    [No Abstract]   [Full Text] [Related]  

  • 20. Bevacizumab in the treatment of metastatic colorectal cancer.
    Caprioni F; Fornarini G
    Future Oncol; 2007 Apr; 3(2):141-8. PubMed ID: 17381413
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.